横纹肌溶解症
医学
急性肾损伤
炎症
肾脏疾病
肾
纤维化
免疫学
内科学
作者
Melania Guerrero‐Hue,Mercedes Vallejo‐Mudarra,Cristina García‐Caballero,Gina Córdoba‐David,Alejandra Palomino‐Antolín,Carmen Herencia,Beatriz Vendrell-Casana,Alfonso Rubio‐Navarro,Jesús Egido,Luis Miguel Blanco‐Colio,Juan Antonio Moreno
标识
DOI:10.1016/j.biopha.2023.115925
摘要
Rhabdomyolysis is a severe clinical syndrome associated to acute kidney injury (AKI) and chronic kidney disease (CKD). TWEAK/Fn14 signaling axis regulates renal inflammation and tubular cell death. However, the functional role of TWEAK/Fn14 in rhabdomyolysis remains unknown. Rhabdomyolysis was induced in wild-type, TWEAK- and Fn14-deficient mice or mice treated with TWEAK blocking antibody. Renal injury, inflammation, fibrosis and cell death were assessed. Additionally, we performed in vivo and in vitro studies to explore the possible signalling pathways involved in Fn14 regulation. Fn14 renal expression was increased in mice with rhabdomyolysis, correlating with decline of renal function. Mechanistically, myoglobin (Mb) induced Fn14 expression via ERK and p38 pathway, whereas Nrf2 activation diminished Mb-mediated Fn14 upregulation in cultured renal cells. TWEAK or Fn14 genetic depletion ameliorated rhabdomyolysis-associated loss of renal function, histological damage, tubular cell death, inflammation, and expression of both tubular and endothelial injury markers. Deficiency of TWEAK or Fn14 also decreased long-term renal inflammation and fibrosis in mice with rhabdomyolysis. Finally, pharmacological treatment with a blocking TWEAK antibody diminished the expression of acute renal injury markers and cell death and lessened residual kidney fibrosis and chronic inflammation in rhabdomyolysis. TWEAK/Fn14 axis participates in the pathogenesis of rhabdomyolysis-AKI and subsequent AKI-CKD transition. Blockade of this signaling pathway may represent a promising therapeutic strategy for reducing rhabdomyolysis-mediated renal injury. Spanish Ministry of Science and Innovation, ISCIII and Junta de Andalucía.
科研通智能强力驱动
Strongly Powered by AbleSci AI